Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2020 2
2021 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. Chiorean EG, et al. Among authors: bathini vg. Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802160 Free PMC article. Clinical Trial.
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R. Li T, et al. Among authors: bathini vg. Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28. Clin Lung Cancer. 2017. PMID: 27919627 Free PMC article. Clinical Trial.
Estimates of the burden of human rabies deaths and animal bites in India, 2022-23: a community-based cross-sectional survey and probability decision-tree modelling study.
Thangaraj JWV, Krishna NS, Devika S, Egambaram S, Dhanapal SR, Khan SA, Srivastava AK, Mishra A, Shrinivasa B, Gour D, Madhukar M, Verma N, Sharma P, Soni RK, Ramasamy S, Mohandas S, Baidya S, Rehman T, Yeldandi VV, Singh A, Sreedevi A, Tandale BV, Purakayastha DR, Reddy MM, Toppo M, Solanki NV, Ghosh P, Jaiswal P, Vyas S, Das S, Palo SK, Prasanth V, Rozario AGA, Durairajan C, Delli A, Sasi A, Pandiyan C, Ashwathnarayana DH, Joy S, Isloor S, Sudarshan MK, Rahi M, Murhekar MV; Human Rabies Study Collaborators. Thangaraj JWV, et al. Lancet Infect Dis. 2024 Sep 30:S1473-3099(24)00490-0. doi: 10.1016/S1473-3099(24)00490-0. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39362224
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.